Biostock article on the TENDU trial and the TET-platform

“Ultimovacs’ TENDU trial is a clinical phase I study aimed at testing the company’s TET platform for cancer vaccine development in prostate cancer patients. The study was initiated earlier this year with the first cohort of patients; now the company has announced dosing the first patient in the second of three cohorts for the TENDU study.”

Read the full article here